To Observe the Effect of Low-dose Peginterferon α-2a and Ribavirin Treatment of Decompensated Hepatitis C Cirrhosis

Objective To study the patients with cirrhosis of the liver decompensation period of hepatitis c, observe choice interferon alpha 2 a small dose of polyethylene glycol(Peg- interferons alpha 2 a) and ribavirin completed after treatment for clinical treatment. Methods 70 patients with hepatitis c cirrhosis of the liver decompensation period from January 2013 to January 2015. Through the stochastic indicator method complete hepatitis cirrhosis patients randomized, C2 group of 35 cases(control group) : clinical choose the method of conventional treatment, C1 group(observation group of 35 cases) : clinical choose Peg- interferons alpha-2 a plus ribavirin treatment method. Compared to two kinds of hepatitis, liver cirrhosis patients in such aspects as clinically relevant indicators show the difference. Results Two groups of patients with cirrhosis of the liver decompensation period of hepatitis c after completion of clinical treatment in ALT, propagated and AST, C1 group is obviously better than the group of C2 hepatitis cirrhosis patients(P0.05). In terms of liver fibrosis indexes, C1 group is obviously better than the group of C2 hepatitis cirrhosis patients(P0.05). Conclusion For patients with cirrhosis of the liver decompensation period of hepatitis c, clinical choose Peg- interferons alpha 2 a and method of ribavirin treatment, can effectively improve liver fibrosis indexes such as, in patients with significantly alleviate the clinical symptoms of patients with hepatitis cirrhosis of the liver, will eventually decompensation period of hepatitis c effective to improve the quality of life of patients with cirrhosis.